Dapaconazole

Drug Profile

Dapaconazole

Alternative Names: BL-123; BL-125; Zilt

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Biolab Sanus Farmaceutica
  • Class Antifungals; Chlorophenols; Imidazoles; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Tinea pedis

Most Recent Events

  • 31 Jan 2017 Biolab Sanus Farmaceutica withdraws a phase III trial prior to enrollment for Tinea pedis in Brazil (NCT02606383)
  • 12 Nov 2015 Biolab Sanus Farmaceutica plans a phase III trial for Tinea pedis in Brazil (NCT02606383)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top